Literature DB >> 8257689

Direct identification of an extracellular agonist binding site in the renal V2 vasopressin receptor.

E Kojro1, P Eich, G Gimpl, F Fahrenholz.   

Abstract

To purify the renal V2 receptor and identify domains involved in hormone binding, photoaffinity labeling of the membrane-bound bovine V2 receptor with a tritium-labeled photoreactive vasopressin agonist was performed. The labeled 30,000 M(r) protein was purified to homogeneity by anion-exchange chromatography, isoelectric focusing, gel filtration, gel electrophoresis, and reversed-phase HPLC. N-terminal sequencing showed that the isolated protein which contains the covalently bound hormonal ligand, represents an N-terminal truncated bovine V2 receptor. The purified labeled V2 vasopressin receptor protein was digested with V8 protease, and peptide fragments were isolated. Protein microsequencing and comparison with the cDNA sequence of a cloned PCR product identified two extra- and two intracellular peptides of the bovine V2 receptor. Radioactivity was incorporated into two amino acid residues localized in the second extracellular domain. Our results indicate that this extracellular domain is involved in peptide agonist binding of the V2 receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257689     DOI: 10.1021/bi00212a020

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor.

Authors:  H Hausmann; A Richters; H J Kreienkamp; W Meyerhof; H Mattes; K Lederis; H Zwiers; D Richter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors.

Authors:  J Howl; M Wheatley
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

Review 3.  Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family.

Authors:  J Peter; H Burbach; R A Adan; S J Lolait; F W van Leeuwen; E Mezey; M Palkovits; C Barberis
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

4.  Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression.

Authors:  S R Hawtin; A R Davies; G Matthews; M Wheatley
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

5.  Extrapituitary expression of the rat V1b vasopressin receptor gene.

Authors:  S J Lolait; A M O'Carroll; L C Mahan; C C Felder; D C Button; W S Young; E Mezey; M J Brownstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

Review 6.  Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.

Authors:  B Mouillac; M Manning; T Durroux
Journal:  Mini Rev Med Chem       Date:  2008-09       Impact factor: 3.862

7.  Molecular modeling of the human vasopressin V2 receptor/agonist complex.

Authors:  C Czaplewski; R Kaźmierkiewicz; J Ciarkowski
Journal:  J Comput Aided Mol Des       Date:  1998-05       Impact factor: 3.686

8.  Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.

Authors:  B Chini; B Mouillac; Y Ala; M N Balestre; S Trumpp-Kallmeyer; J Hoflack; J Elands; M Hibert; M Manning; S Jard
Journal:  EMBO J       Date:  1995-05-15       Impact factor: 11.598

9.  Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.

Authors:  Federica Prosperi; Yoko Suzumoto; Pierluigi Marzuillo; Vincenzo Costanzo; Sabina Jelen; Anna Iervolino; Stefano Guarino; Angela La Manna; Emanuele Miraglia Del Giudice; Alessandra F Perna; Miriam Zacchia; Emmanuelle Cordat; Giovambattista Capasso; Francesco Trepiccione
Journal:  Sci Rep       Date:  2020-10-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.